4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 27 Issue 4
Jun.  2013
Turn off MathJax
Article Contents
Subhasree Nag, Jiangjiang Qin, Kalkunte S. Srivenugopal, Minghai Wang, Ruiwen Zhang. The MDM2-p53 pathway revisited[J]. The Journal of Biomedical Research, 2013, 27(4): 254-271. DOI: 10.7555/JBR.27.20130030
Citation: Subhasree Nag, Jiangjiang Qin, Kalkunte S. Srivenugopal, Minghai Wang, Ruiwen Zhang. The MDM2-p53 pathway revisited[J]. The Journal of Biomedical Research, 2013, 27(4): 254-271. DOI: 10.7555/JBR.27.20130030

The MDM2-p53 pathway revisited

Funds: 

This work was supported by the National Institutes of Health (NIH) grants R01 CA112029 and R01 CA121211 and a Susan G Komen Foundation grant BCTR0707731 (to R.Z.).

More Information
  • Received Date: March 14, 2013
  • The p53 tumor suppressor is a key transcription factor regulating cellular pathways such as DNA repair, cell cycle, apoptosis, angiogenesis, and senescence. It acts as an important defense mechanism against cancer onset and progression, and is negatively regulated by interaction with the oncoprotein MDM2. In human cancers, the TP53 gene is frequently mutated or deleted, or the wild-type p53 function is inhibited by high levels of MDM2, leading to downregulation of tumor suppressive p53 pathways. Thus, the inhibition of MDM2-p53 interaction presents an appealing therapeutic strategy for the treatment of cancer. However, recent studies have revealed the MDM2-p53 interaction to be more complex involving multiple levels of regulation by numerous cellular proteins and epigenetic mechanisms, making it imperative to reexamine this intricate interplay from a holistic viewpoint. This review aims to highlight the multifaceted network of molecules regulating the MDM2-p53 axis to better un-derstand the pathway and exploit it for anticancer therapy.

Catalog

    Article Metrics

    Article views (8857) PDF downloads (2419) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return